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Introduction: The first-line regimen for tuberculosis (TB) 
treatment comprises Isoniazid, Rifampicin, Pyrazinamide, 
and Ethambutol. However, these drugs are known to 
potentially cause hepatotoxicity. This study aimed to 
evaluate hepatotoxicity incidence in patients during 
intensive phase of anti-tuberculosis treatment focusing on 
post-incidence therapy. Methods: The study involved 
pulmonary TB patients who were admitted to the National 
Lung Health Center due to hepatotoxicity after receiving 
fixed-dose combination of antituberculosis drugs (FDC- 
AT) in September-October 2019. Drug-related 
hepatotoxicity is defined as an increase in serum alanine 
aminotransferase (ALT) or aspartate aminotransferase 
(AST) levels greater than 2.5 times of the normal upper 
limit (ULN) with an increase in bilirubin level. Results: 
There were 8 patients admitted to the center due to 
hepatotoxicity, 4 of them experienced grade 3 (severe) 
hepatotoxicity, during which the ALT, AST, bilirubin levels 
increased 5-10 times of the ULN. The post-hepatotoxicity 
treatment includes the cessation of FDC-AT treatment 
followed by hepatoprotective supplements. Following two 
weeks of treatments, the biomarker levels of two out of 
four patients went back to normal and the AT therapy was 
resumed. Meanwhile, the other two patients continued to 
receive the hepatoprotective therapy for up to 8 weeks. 
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Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis that 
mainly attacks the lungs (pulmonary TB), but can also affect other organs 
(extrapulmonary TB) 1. The first-line antituberculosis (AT) treatment comprises Isoniazid 
(INH), Rifampicin (RMP), Pyrazinamide (PZA), and Ethambutol (EMB) in a fixed-dose 
combination 2. Unfortunately, three out of the four antituberculosis drugs, such as 
isoniazid, rifampicin, and pyrazinamide, may produce reactive metabolites or modulate 
liver enzyme activities, and therefore, potentially induce hepatotoxicity 3. The 
combination of INH was initially considered safe without side effects, but in the early 
1970s several studies with large sample sizes suggested that INH can actually induces 
hepatotoxicity. The frequency of these effects varies from population to population: about 
1–30 in 100 individuals on INH and RMP treatment 4. 
Drug induced hepatotoxicity (DIH) can be defined as liver damage in the form of 
serious adverse reactions with significant morbidity, and even cause death (rarely) 5. It 
can be detected using liver function test by measuring the aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) levels 6. If hepatotoxicity occurs, it can force 
treatment termination, which may lead to increased risk of AT drug resistance and worse 
outcome in TB patients 7. The guidelines also recommend treating the AT-induced 
hepatotoxicity by changing the antituberculosis treatment to a lower-risk regimen 8. In 
addition, hepatoprotective supplements, such as curcumin, can be used to improve 
hepatotoxicity 9. The aim of this study is to report the cases of AT drug-induced 
hepatotoxicity at the National Lung Health Center in Makassar focusing on the 
effectiveness of the hepatoprotective treatment following the incidence. 
2. METHODS 
 
The study involved pulmonary tuberculosis patients in National Lung Health 
Center Makassar who was admitted due to hepatotoxicity clinical signs after receiving 
fixed dose combination of anti-tuberculosis drugs (FDC AT) during the period of 
September-October 2019. All patients have signed the informed consent prior to data 
acquisition. The presence of hepatotoxicity is confirmed if the increase in serum alanine 
aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin  is  more than 
2.5 times of the upper limit of normal (ULN) with or without symptoms of hepatitis 5. The 
severity of hepatotoxicity is divided into mild (if the ALT or AST increases <2.5 times 
ULN), moderate (ALT or AST 2.5-5 times that of ULN), severe (ALT or AST 5-10 times 
that of ULN) and very severe (ALT or AST >10 times ULN) and for bilirubin values >1.2 
transaminase level back to normal, a different AT regimen 
was prescribed. Conclusions: The cessation of FDC-AT 
and the use of hepatoprotective supplements for two to 
eight weeks were able to alleviate the AT-induced severe 
hepatotoxicity. A close monitoring of liver biomarkers is 
warranted to prevent the incidence of hepatotoxicity in 
patients receiving antituberculosis 
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mg/dL 6,7. All protocols have been approved by the Institutional Research Ethic 
Committee with ethical clearance number of 185/UN4.6.4.5.31/PP36/2020. 
2.1 Inclusion criteria 
Adult (>17 years old) TB patients treated with intensive phase FDC-AT (category 1) and 
were diagnosed with hepatotoxicity at the National Lung Health Center Makassar during 
September-October 2019. 
2.2 Exclusion Criteria 
Patients who have suffered from liver disease before starting TB treatment or received 
AT therapy other than FDC AT category 1, or patients with HIV complication, or patients 
who were prescribed with statin, anticonvulsant, and antiretroviral drugs since those 












Figure 1. The flow diagram of the study 
 
There were 8 patients who met the inclusion criteria and all of them experienced 
hepatotoxicity during the intensive phase of FDC-AT treatment. From 8 patients, there 
was 3 patients admitted with grade 1 hepatotoxicity (ALT and AST <2.5 times the ULN), 
1 patient with grade 2 hepatotoxicity (ALT 2.5-5 times the ULN), and 4 had grade 3 
hepatotoxicity (ALT, AST, bilirubin 5-10 times the ULN) (see table 1). 
 
Table 1. The demography and liver biomarker levels of patients diagnosed with hepatotoxicity at the 
















Sex ALT AST Bilirubin 
Hepatotoxicit 
y Grade 
    (U/L)  (U/L)  (mg/dl)   
A Male 45 70 75 118 1.75 3 days 1 (Mild) 
B Male 44 38 121 93 1.6 3 weeks 1 (Mild) 
C Female 33 35 101 73 0.86 8 weeks 1 (Mild) 
D Female 30 38 137 74 2.01 8 weeks 2 (Moderate) 
E Female 20 38 250 405 1.34 10 days 3 (Severe) 
F Male 61 55 279 285 13.00 8 weeks 3 (Severe) 
G Male 50 81 358 144 2.03 4 weeks 3 (Severe) 
H Male 27 45 343 330 1.82 5 days 3 (Severe) 
Patients with ALT and AST 
levels <5 ULN (n=4) 
Patients with elevated ALT and AST levels 
(n=8) 
Patients without 
hepatotoxicity clinical signs 
(n=26) 
Adult TB patients receiving antituberculosis 
treatment at National Lung Center in 
September-October 2019 (n=34) 
Patients with elevated ALT and AST levels 
5-10 ULN (n=4) 
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In this report, we focus on the severe cases and how the post incidence treatment can 
alleviate the severity of FDC-AT induced hepatotoxicity. 
3.1 Case 1 
Patient E, female, aged 20 years old, admitted to the National Lung Center 
complaining vomiting excessively, at least four times a day. The patient also experienced 
heartburn, coughing, left abdominal pain and dyspepsia. The patient was prescribed with 
antiemetic medication, such as ondansetron injection and omeprazole injection, to treat 
the symptoms. The patient had a history of tuberculosis and had been taking FDC-AT 
for 10 days. Blood analysis showed the AST level of 405 U/L and ALT of 250 U/L. This 
suggests that patients experienced impaired hepatic function or grade 3 (severe), as 
there was an increase in ALT and AST of 5-10 times ULN (AST and ALT: 251-500 U/L). 
The FDC-AT treatment was terminated and the patients was treated with 
hepatoprotective supplement in the form of Curcuma tablet (Curcuma xanthorrhiza 20 
mg) every 8 hours and Hepatin (750 mg) every 12 hours. Four days after the 
hepatoprotective drug administration, the patient's AST and ALT levels were re- 
examined and showed an improvement (AST 29 U/L and ALT 235 U/L). Two weeks later, 
after AST and AST values returned to normal, the patient resumed the FDC-AT treatment 
with close monitoring. 
3.3 Case 2 
Patient F, male, aged 61 years, admitted to the national Lung Center due to 
shortness of breath, cough with phlegm, and lethargic. The patient had been suffered 
from tuberculosis and started FDC-AT treatment in the last 2 months. The patient was 
hospitalized at the National Lung Health Center for 16 days. Patient’s AT treatment was 
discontinued as the sign of hepatotoxicity was confirmed by a mark elevation of AST 
(285 U/L), ALT (279 U/L), and total bilirubin (13.00 mg/dL) levels. As the increase in AST 
and ALT values were 5-10 times ULN, the patients were diagnosed with grade 3 (severe) 
hepatotoxicity). The patient was then prescribed with hepatoprotective drugs, including 
Curcuma for every 8 hours and Hepatin for every 12 hours. After administering the 
hepatoprotective drug for 2 weeks, the AST level decreased to 30 U/L, the ALT to 22 
U/L. Although at the time, the bilirubin level was still above the ULN (2.65 mg/dl). As soon 
as the transaminase enzymes were back to normal, the administration antituberculosis 
was resumed, however, the form of FDC AT was replaced with single tablet combination 
of AT drugs to allow time intervals between AT drug administration. 
3.2 Case 3 
Patient G, aged 50 years old, male, with a history of tuberculosis and FDC-AT 
treatment for 2 months, complaint for shortness of breath, coughing, chest pain, 
headaches, and vomiting with a frequency of four times a day. The result of blood 
examination before consuming FDC-AT showed a normal AST (27 U/L) and ALT (17 
U/L) levels. Following the FDC-AT treatment for 4 weeks, the AST level rose to 358 U/L 
and ALT to 144 U/L. This patient was diagnosed with grade 3 (severe) hepatotoxicity, 
with an increase in ALT, AST, and bilirubin 5-10 times of the ULN. The FDC-AT treatment 
was terminated and the hepatoprotective supplement was prescribed in the form of 
curcuma tablets. Two weeks after curcuma treatments, the AST and ALT levels were re- 
examined. At that time, the AST and ALT levels of the patients were lower but they were 
still above the normal levels (137 U/L and 155 U/L for AST and ALT, respectively). The 
hepatoprotective therapy was continued for 8 weeks. Once the AST and ALT levels 
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returned to normal, the FDC-AT regimen was changed to the combination of AT single 
tablets, starting from a lower dose with a close monitoring of hepatotoxicity signs. 
3.4 Case 4 
Patient H, 27 years old male, was treated due to hemoptysis or coughing up blood 
for 2 days, left chest pain, heartburn, nausea, vomiting and weakness. The patients had 
been consuming FDC-AT for 5 days when the clinical symptoms emerged. At the time of 
admission, the AST level was 330 U/L and ALT was 343 U/L, which indicates level 3 
(severe) hepatotoxicity with elevated AST and ALT values of 5-10 times ULN. The FDC- 
AT treatment was immediately discontinued and hepatoprotective drug was prescribed 
in the form of Curcuma and Hepatin tablets. In addition to the administration of 
hepatoprotective drugs, the patient also received omeprazole injection therapy (40 mg 
i.v daily), codeine tablet (20 mg per 8 hours), and tranexamic acid injection to treat 
symptoms of heartburn, nausea, vomiting and bloody cough. Following the therapy, the 
AST level of the patients decreased near the ULN (78 U/L). However, the ALT level was 
still markedly elevated (389 U/L). For this patient, the AT regimen was changed to a 




FDC AT regimen has been recommended by WHO as an efficient regimen to 
treat TB. However, many hepatotoxicity cases in TB patients have been reported after 
consuming this regimen. An animal model study has shown the administration of FDC 
AT in rats started to induce liver dysfunction within 2 weeks of administration 10. In 
humans, we found the incidence of hepatotoxicity can develop as soon as 3 days 
following initiation of FDC AT treatment. 
To prevent hepatotoxicity, several clinics and hospitals in Indonesia has 
introduced the use of hepatoprotective supplements from natural sources, such as 
Curcuma xanthorriza, Silymarin, Echinacea extract, etc. Our study showed that in severe 
cases, the temporary cessation of AT drugs and initiation of herbal supplements to 
patients seemed to be effective to improve hepatotoxicity in two out of four patients. 
Consistent with this finding, a previous study has shown Curcuma supplement was able 
reduce the incidence and severity of hepatotoxicity, shown by a significant decrease in 
ALT and AST values in TB patients after 4 weeks of treatments 9. However, in our study, 
the other two patients did not show a decrease in either ALT or bilirubin even after 2 
weeks of receiving hepatoprotective therapy. For one of these patients, the AT treatment 
regimen was changed into streptomycin, ethambutol, and rifampicin. This is consistent 
with the guidelines for the management of Drug-Induced Hepatotoxicity (DIH) 7. 
The use of herbal supplementation in Indonesia is not only popular in TB patients, 
but also for other liver injury condition as demonstrated by other clinical study. It has 
been demonstrated that herbal supplementation of 75 mg Curcuma xanthoririza, 50 mg 
Arcangelisia flava, 100 mg Nigella sativa, 100 mg Kleinhovia hospita and 100 mg 
Ophiocephalus striatus as hepatoprotectors could reduce the levels of ALT by 45.06% 
and AST by 48.63% after 7 days of treatments in patients with chronic hepatitis 10. 
Curcumin has also been used for the treatment of inflammatory disorders of the liver as 
an antioxidant since it has the capability to increase glutathione S-transferase (GST). 
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This may improve the free radical scavenger activity of GST and protects cells from 




The use of FDC-AT in tuberculosis patients can cause liver dysfunction or 
hepatotoxicity. The management of hepatotoxicity applied in the National Lung Health 
Center Makassar is the termination of FDC-AT and initiation of hepatoprotective therapy 
in the form of herbal supplementation. This therapy is usually well responded; however, 
in severe cases, it failed to normalized two out of four patients’ ALT and bilirubin levels. 
For patients who regained normal ALT and AST levels, the continuation of the first-line 
AT drugs was recommended, with a close monitoring of hepatotoxicity symptoms. On 
the other hand, switching to streptomycin regimen was required for patients whose liver 
biomarkers did not return to normal after 8 weeks of hepatoprotective treatment. Further 
research is required to investigate if the improvement of hepatotoxicity occurred due to 
the herbal supplementation or simply because of the discontinuation of FDC AT therapy. 
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